Acorda Therapeutics Begins Second Phase 1 GGF2 Trial In Heart Failure – NASDAQ
Acorda Therapeutics Begins Second Phase 1 GGF2 Trial In Heart FailureNASDAQ(RTTNews.com) – Acorda Therapeutics Inc. ( ACOR ) today announced that the first patient has been enrolled in the second trial of Glial Growth Factor 2 or GGF2. This Phase 1b si…
